Ortho-carboranyl glycosides for the treatment of cancer by boron neutron capture therapy

Bioorg Med Chem. 2001 Jul;9(7):1747-52. doi: 10.1016/s0968-0896(01)00061-x.

Abstract

Distinct biological properties of the ortho-carboranyl (1,2-dicarba-closo-dodecaboranyl) glycosides 1, 2 and 3 were evaluated to estimate the suitability of these compounds for cancer treatment by boron neutron capture therapy. The boron uptake into B16-Melanoma cells was significantly higher by incubating the cells with aqueous solutions of carboranyl glucoside 1 (11.2 ppm after 3h), lactoside 2 (13.2 ppm after 12h) and maltoside 3 (20.0 ppm after 24h) compared with solutions of clinically used p-boronophenylalanine (BPA) 5 (3.1 ppm after 24h). Carboranyl maltoside 3 was more effective than boron-10 enriched 5 in killing C-6 rat glioma cells by incubating the cells with the compound and subsequent treatment with thermal neutrons. 3 was also administrated iv, in concentrations of 25 mg boron/kg body weight to rats bearing brain tumors. After a period of 4h after administration the concentration of boron in the tumor tissue was 3.0 ppm.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Boron Neutron Capture Therapy*
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / pathology
  • Glioma / drug therapy*
  • Glioma / pathology
  • Glycosides / chemistry
  • Glycosides / therapeutic use*
  • Male
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Rats
  • Rats, Wistar

Substances

  • Glycosides